Viewing Study NCT02792218

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:38 AM
Ignite Modification Date: 2026-03-05 @ 11:31 AM
Study NCT ID: NCT02792218
Status: COMPLETED
Last Update Posted: 2021-10-01
First Post: 2016-06-02
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsing Multiple Sclerosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Relapsing multiple sclerosis View
None Ofatumumab View
None adult View
None OMB157 View
None multiple sclerosis View
None T1 lesions View
None T2 lesions View
None relapse View
None GD-enhancing MRI View
None McDonald criteria View
None RRMS View
None SPMS View